The DEA has designated Xcopri (cenobamate; SK Life Science) as a schedule V controlled substance, indicating a lower potential for abuse.
The RNS System consists of a small neurostimulator that is surgically implanted into the skull, delivering an electrical stimulation to the brain via leads when abnormal activity is detected.
In patients with a known diagnosis of cirrhosis, hepatic exacerbations may increase the risk for hospitalization for epilepsy and status epilepticus.
Self-monitoring behaviors may serve as a potential mediator of therapeutic change for patients with epilepsy.
Taro Pharmaceuticals announced the voluntary recall of 2 lots of Phenytoin Oral Suspension 125mg/mL packaged in 237mL bottles that may not resuspend properly when shaken, which can potentially result in under or overdosing.
The Food and Drug Administration (FDA) has accepted for review the New Drug Application for Libervant® (diazepam; Aquestive Therapeutics) buccal film for the management of seizure clusters.
Epidiolex is currently approved in the US to treat seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
Road proximity is associated with an increased incidence of specific neurologic disorders.
The FDA has expanded the approval of vigabatrin to include treatment of refractory complex partial seizures in patients aged 2 to <10 years of age.
The FDA has approved Valtoco (diazepam nasal spray; Neurelis) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older.